Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice  Lysanne.
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Vuong Thi Ngoc Lan, Nguyen Khanh Linh, Ho Manh Tuong, P. C
Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,
Ovarian morphology and function during growth hormone therapy of short girls born small for gestational age  Jeanette Tinggaard, M.D., Rikke Beck Jensen,
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome  Sigrun B. Kjøtrød, M.D., Arne.
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.
Evaluation of the immature human oocytes from unstimulated cycles in polycystic ovary syndrome patients using a novel scoring system  Shan Liu, M.D.,
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
Biomarkers of ovarian response: current and future applications
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F
Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Evaluating the performance of serum antimullerian hormone concentration in predicting the live birth rate of controlled ovarian stimulation and intrauterine.
Robert F. Casper, M.D.  Fertility and Sterility 
Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study  Ahmet Erdem, M.D., Mehmet Erdem,
Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration 
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular.
Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced.
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Retrieval of immature oocytes after chemotherapy for Hodgkin's disease and prolonged ovarian down-regulation with gonadotropin-releasing hormone agonist 
Increased secretion of amylin in women with polycystic ovary syndrome
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis 
Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone.
Fertility and Sterility
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial  Antoni J. Duleba, M.D.,
Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.
Paolo Moghetti, M.D.  Fertility and Sterility 
Validation of a prediction model for the follicle-stimulating hormone response dose in women with polycystic ovary syndrome  Madelon van Wely, Ph.D.,
Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist  Casper P. Hagen, M.D., Kaspar Sørensen,
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Inappropriate gonadotropin secretion in polycystic ovary syndrome
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation  Reshef.
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization  Rongrong Tan, M.M.Sc., Danhua Pu,
Presentation transcript:

Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi Ngoc Lan Vuong, M.D., Manh Tuong Ho, M.D., Tan Duc Ha, M.D., Huy Tuan Phung, M.D., Gia Bao Huynh, M.Sc., Peter Humaidan, D.M.Sc.  Fertility and Sterility  Volume 105, Issue 2, Pages 356-363 (February 2016) DOI: 10.1016/j.fertnstert.2015.10.014 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 1 CONSORT flow diagram. AMH = antimüllerian hormone; COS = controlled ovarian stimulation; OPU = oocyte pick-up; PCOS = polycystic ovary syndrome. Fertility and Sterility 2016 105, 356-363DOI: (10.1016/j.fertnstert.2015.10.014) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Serum concentrations (mean ± SD) of LH (A), FSH (B), E2 (C), and P (D) during the follicular phase and early luteal phase by treatment group (GnRH-a [triptorelin] dose). *P<.05 for LH and P. OPU = oocyte pick-up. Fertility and Sterility 2016 105, 356-363DOI: (10.1016/j.fertnstert.2015.10.014) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.